Pfizer
Health Care |
Pharmaceutical Companies
6125 Edloe St, Houston, TX 77005
Recent News About Pfizer
View More
-
WILMINGTON, Del. (Legal Newsline) – Excess insurance will pick up the tab for some of the litigation against Pfizer regarding its anti-inflammatory drug Celebrex.
-
NEW YORK (Legal Newsline) – Pfizer says the federal government is keeping it from getting two of its drugs to patients with a rare and fatal heart condition.
-
The Trump Justice Department, following a tougher policy toward dubious False Claims Act lawsuits by private citizens, has moved to dismiss a pair of lawsuits by a former hedge-fund manager who shorted stock in pharmaceutical companies he accused of a wide-ranging price-fixing conspiracy.
-
OLYMPIA, Wash. (Legal Newsline) – On Nov. 1, the Supreme Court of the State of Washington adopted the apparent manufacturer doctrine in a case concerning a man’s exposure to asbestos products that allegedly ultimately led to his sickness and passing.
-
NEW YORK — Pfizer Inc. has agreed to pay more than $2.5 million in penalties to settle charges by the New York State Attorney General's Office of deceptively marketing its co-payment coupon program "Pay No More Than."
-
In an ominous sign for the opioid industry, a New York judge refused to dismiss any of the claims by eight counties against Purdue Pharma, Johnson & Johnson and other prescription opioid manufacturers, saying the plaintiffs had adequately pled violations of everything from consumer protection statutes to the common law of public nuisance.
-
ALBANY, N.Y. (Legal Newsline) - New York lawmakers won't discuss a bill targeting abuses in the asbestos compensation system during today's meeting of the Senate Finance Committee, where the bill, which is similar to legislation passed in 15 states, has sat for three months since being approved by the Judiciary Committee.
-
WASHINGTON (Legal Newsline) — The U.S. Department of Justice announced May 24 that Pfizer Inc., a major pharmaceutical company in New York, will pay $23.85 million after allegations of a massive kickback scheme.
-
Pfizer’s lawsuit, filed in a Pennsylvania federal court in September, alleges Johnson & Johnson’s exclusionary contracts and other anti-competitive practices have denied U.S. patients access to therapeutic options and undermined the benefits of “robust” price competition in the “innovative and growing” biologics marketplace for patients.
-
The federal appeals court, in a ruling this month, said a lower federal court was wrong to rule that no reasonable jury could find the drug maker liable for certain statements made by companies that owned the two pain-relieving drugs Celebrex and Bextra before Pfizer. The shareholders allege Pfizer concealed the risks associated with the two drugs.
-
A major drug manufacturer is the subject of a lawsuit over allegations that its medication packaging deceives consumers. Matthew Fermin, Lichun Huo, Josefina Valdez and Adriana Sousa filed the lawsuit on April 14 against Pfizer, Inc., alleging its Advil ibuprofen dry pills and Liqui-Gels lines were sold with “nonfunctional slack-fill” that violates state law.
-
A class action lawsuit filed in Pennsylvania alleges stock options for a large pharmaceutical company were manipulated illegally.
